Fostiropoulos G, Croydon E A
J Int Med Res. 1982;10(4):204-8. doi: 10.1177/030006058201000402.
A single-blind crossover study of two non-steroidal anti-inflammatory drugs, nabumetone (1000 mg/day) and naproxen (500 mg/day) was performed in thirty patients suffering from definite or classical rheumatoid arthritis. Nabumetone significantly improved the various parameters assessed, while this was not observed with naproxen. The superiority of nabumetone over naproxen appeared for the anti-inflammatory activity (e.g. E.S.R., articular index, P.I.P. joint circumference, grip strength) as well as for the analgesic activity (patient's opinion). The clinical tolerance appeared equally good for both drugs.
对30例确诊或典型类风湿性关节炎患者进行了一项双盲交叉研究，比较两种非甾体抗炎药萘丁美酮（1000毫克/天）和萘普生（500毫克/天）的疗效。萘丁美酮能显著改善所评估的各项指标，而萘普生则未观察到这一效果。在抗炎活性（如血沉、关节指数、近端指间关节周长、握力）以及镇痛活性（患者自评）方面，萘丁美酮均优于萘普生。两种药物的临床耐受性表现相当。
